Stifel Initiates Coverage On Mentari Therapeutics with Buy Rating, Announces Price Target of $30

Benzinga · 2d ago
Stifel analyst Paul Matteis initiates coverage on Mentari Therapeutics (NASDAQ:MTRI) with a Buy rating and announces Price Target of $30.